STAT+: Hospitals and pharma are both on the hook to help fund infrastructure deal
WASHINGTON — Both hospitals and drug makers are on the hook to help pay for…
Category: STAT+
STAT+: Lawmakers ask Defense Department about using a controversial maneuver to lower drug prices
Three years ago, Congress directed the Department of Defense to take steps to lower the…
STAT+: Deep Genomics raises $180 million to automate drug discovery
Brendan Frey, the founder and chief executive of Deep Genomics, thinks the wrong people are…
STAT+: Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales
Top of the morning to you, and a fine one, it is. Delicious cool breezes…
STAT+: For the first time ever, Lander’s White House science office will have an entire wing dedicated to health
WASHINGTON — Eric Lander, the renowned genomics researcher, has kept a low profile in his…
STAT+: Animal rights activists get new ammunition in their battle over a controversial rodent test
In what animal rights activists see as a significant development, a pair of U.K. health…
STAT+: Pharmalittle: Pharma lobbies Congress on global tax proposal; the FDA doc at center of Aduhelm controversy
Rise and shine, everyone, another busy day is on the way. We can tell because…
.jpg)
STAT+: STAT+ Conversations: A conversation on scrutiny facing Epic’s health care algorithms
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Purdue says most creditors voted in favor of contentious bankruptcy plan
In an apparent victory for Purdue Pharma, preliminary voting shows most creditors are in favor…
STAT+: How Biogen found a believer: At the FDA, a hard-nosed regulator was won over on controversial Alzheimer’s drug
When the drug maker Biogen pitched its Alzheimer’s treatment to a panel of independent experts…
STAT+: Microbiome therapy companies face the fallout of failed Seres trial
A frost may be setting in across the microbiome therapeutics space after another clinical trial…
STAT+: Epic’s AI algorithms, shielded from scrutiny by a corporate firewall, are delivering inaccurate information on seriously ill patients
Several artificial intelligence algorithms developed by Epic Systems, the nation’s largest electronic health record vendor,…
STAT+: Most clinical trials failed to meet U.S. transparency requirements for recently approved drugs
In the latest look at clinical trial transparency, a new analysis found that only 26%…
STAT+: Seres Therapeutics’ microbiome therapy for ulcerative colitis falls short in Phase 2 trial
Seres Therapeutics’ highly anticipated clinical trial in ulcerative colitis failed to meet its primary endpoint,…
STAT+: Happify to release prescription app to treat depression under loosened FDA rules
Leveraging Food and Drug Administration regulations loosened during the pandemic, Happify Health, which is best…
STAT+: Pfizer looks to widen access to Covid-19 vaccine in Africa, but advocates say it doesn’t go far enough
Pfizer (PFE) and BioNTech (BNTX) moved Wednesday to widen access to Covid-19 vaccines by striking…
STAT+: Therapy chatbot startup Woebot raises $90 million
Woebot announced Wednesday that it raised a $90 million Series B investment to further the…
.jpg)
STAT+: FDA plans to study whether pharma reps at conference exhibit booths are telling the truth
Pandemics aside, medical conferences are popular destinations for doctors, who are barraged with information about…
STAT+: Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say
If ever there were a cautionary tale for the Food and Drug Administration’s approval of…
STAT+: As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional
In harsh words, the U.S. Department of Justice castigated Purdue Pharma’s proposed bankruptcy plan as…
STAT+: STAT+ Conversations: the revitalization of the antibiotic drug pipeline
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pacific Biosciences to buy smaller DNA sequencing firm for up to $800 million
Pacific Biosciences of California, a maker of DNA sequencing equipment that has seen its stock…
STAT+: San Francisco, Austin, or Raleigh? White House contemplates an out-of-D.C. address for new biomedical research agency
WASHINGTON — The White House isn’t worried about Congress underfunding the new biomedical research agency…
STAT+: Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill
WASHINGTON — The very next day after Rep. Scott Peters attempted to torpedo House Speaker…
STAT+: Advocates urge Biden to name patent office director that could transform drug pricing
As the White House readies to name a new head of the U.S. Patent &…
STAT+: Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in the Netherlands have fined a drug maker $23 million for years of…
STAT+: Cytokinetics drug improves blood flow in patients with inherited form of heart disease
Cytokinetics said Monday that its experimental drug demonstrated statistically significant improvements in blood flow for…
STAT+: Kadmon wins approval for drug to treat chronic graft-versus-host disease
Kadmon Pharmaceuticals won approval from the Food and Drug Administration on Friday to market a…
STAT+: Atul Gawande, bureaucrat: A tough job would await the renowned surgeon at USAID
Atul Gawande has been a renowned surgeon, an award-winning magazine writer and author, a Rhodes…
STAT+: Amid Purdue bankruptcy talks, Connecticut attorney general accuses some Sacklers of intimidation
In the latest drama surrounding Purdue Pharma, Connecticut Attorney General William Tong lashed out at…
STAT+: Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug
Happy Friday, everyone! This is Elizabeth Cooney, sitting in for Ed Silverman this fine morning….
STAT+: Expert panel votes down Fibrogen’s anemia pill due to safety risks, making U.S. approval unlikely
A panel of outside experts convened by the Food and Drug Administration concluded Thursday that…
STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
A prominent panel of medical experts unanimously voted that there is no evidence to suggest…
STAT+: DeepMind and and a rival release dueling code for protein-folding AI
Computational biologists have been on tenterhooks for the past seven months, ever since DeepMind took…
STAT+: U.K. issues record fine to drug makers for price gouging and collusion schemes
After a lengthy investigation, the U.K. antitrust regulator has fined several drug makers a record-setting…
STAT+: Pharmalittle: FDA head admits possible missteps in Alzheimer’s drug approval; two major health systems won’t administer Biogen drug
Top of the morning to you and a fine one, it is. Moderate temperatures and…
STAT+: The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug
WASHINGTON — The Food and Drug Administration last month foisted a nearly impossible decision on…
STAT+: Apple provides narrow glimpse at research behind new walking steadiness feature
Apple is gearing up to release a new metric called Walking Steadiness aimed at preventing…
STAT+: Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal
WASHINGTON — Senate Democrats intend to include several drug pricing policies in their $3.5 trillion…
STAT+: FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug
In an embarrassing rebuke, the Food and Drug Administration has scolded Amgen (AMGN) over a…
STAT+: Pharmalittle: Half-dozen big insurers won’t cover new Alzheimer’s drug; Medicaid could spend up to $2.2 billion on the Biogen drug
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: ‘’This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug
At least half-a-dozen private health insurers in some of the nation’s largest states are balking…
STAT+: Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit
A federal judge dropped allegations that three drug makers engaged in antitrust practices by scheming…
STAT+: ‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug
Though a rival’s Alzheimer’s drug reached the market first, the CEO of Eli Lilly spoke…
STAT+: Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year
A pricey new Alzheimer’s drug already mired in controversy could cost Medicaid anywhere from $720…
STAT+: Pharmalittle: Medicare starts coverage review for Biogen Alzheimer’s drug; U.S. needs more data before deciding on Covid booster shot
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Patient data company Truveta raises $95 million, secures new hospital partners
A company formed to aggregate and sell de-identified data on millions of American patients has…
STAT+: If everyone already knows about a new biotech startup, why does it ‘launch’?
Biotech companies often linger in a corporate version of Schrödinger’s box — of existence and…
STAT+: Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug
WASHINGTON — Federal officials on Monday announced the agency will start a process that could…
STAT+: Dozens of generic makers and pharmacies won’t face lawsuits over Zantac and cancer risks
A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in…